Skip to main content
Open Access Publications from the University of California

Difficult Intraoperative Heparinization Following Andexanet Alfa Administration

  • Author(s): Watson, C. James
  • Zettervall, Sara L.
  • Hall, Matthew M.
  • Ganetsky, Michael
  • et al.

Direct oral anticoagulants are now commonplace, and reversal agents are recently becoming available. Andexanet alfa (AnXa), approved by the United States Food and Drug Administration in 2018, is a novel decoy molecule that reverses factor Xa inhibitors in patients with major hemorrhage. We present a case of a 70-year-old man taking rivaroxaban with hemodynamic instability from a ruptured abdominal aortic aneurysm. He received AnXa prior to endovascular surgery, and intraoperatively he could not be heparinized for graft placement. Consideration should be given to the risks and benefits of AnXa administration in patients who require anticoagulation after hemorrhage has been controlled.

Main Content
Current View